Premium
Tailored strategy for AML patients receiving allogeneic peripheral blood stem cell transplantation
Author(s) -
Sohn Sang Kyun,
Kim Jong Gwang,
Kim Dong Hwan
Publication year - 2006
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.20078
Subject(s) - medicine , transplantation , stem cell , leukemia , disease , peripheral blood stem cells , myeloid leukemia , intensive care medicine , oncology , immunology , hematopoietic stem cell transplantation , genetics , biology
Considering the heterogeneity of acute myelogenous leukemia (AML), along with the pros and cons of allogeneic peripheral blood stem cell transplantation (PBSCT), a tailored strategy is needed to minimize the transplant‐related mortality and maximize the transplant outcomes in AML patients exhibiting certain factors that have an impact on the post‐transplant quality of life and outcomes. The factors that need to be considered when tailoring a strategy in an allogeneic PBSCT setting include the recipient's performance status and co‐morbid disease include AML risk stratification, disease status, expected severity of graft‐versus‐host disease, and the necessity of a graft‐versus‐leukemia effect. Accordingly, this review article describes a possible tailoring strategy for AML patients receiving allogeneic PBSCT based on certain factors influencing the transplant outcome. J Clin Apheresis © 2006 Wiley‐Liss, Inc.